A Karolinska Institutet-led study reported that low-dose endoxifen, an active metabolite of tamoxifen, can significantly reduce mammographic breast density with fewer side effects, with results published in the Journal of the National Cancer Institute. The trial data support a potential shift from standard tamoxifen dosing toward dose-reduced endoxifen for breast cancer prevention. Mammographic breast density is used as a risk marker for future breast cancer, and lowering it is intended as an intermediate outcome rather than a direct measure of cancer incidence. The study’s focus on minimizing side effects addresses a key barrier for long-term preventive endocrine strategies. The article characterizes the findings as a promising advancement for prevention approaches, especially for patients who may not tolerate full-dose tamoxifen. For developers, the report highlights an opportunity to revisit existing endocrine mechanisms with different exposure targets and tolerability profiles rather than starting from entirely new drug classes.